Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Citi downgraded telehealth company Hims & Hers Health (NYSE:HIMS) to Sell from Neutral and upgraded value-based care provider agilon health (NYSE:AGL) to Neutral from Sell on Friday as part of its ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...